Ferrocene-based antimalarials

Future Medicinal Chemistry

Volumn 4, Issue 6, 2012, Pages 783-797

  Roux, Clément ^a   Biot, Christophe ^b  

^a Begbroke Science Park   (United Kingdom)

^b UNIV LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2,2' AZINO BIS(3 ETHYLBENZOTHIAZOLINE 6 SULPHONIC ACID DIAMMONIUM SALT); AMODIAQUINE; ANTIMALARIAL AGENT; ARTEMETHER; ARTEMISIN; ARTEMISITENE; ARTESUNATE; ATOVAQUONE; BENFLUMETOL; CHLOROQUINE; CIPROFLOXACIN; DOXYCYCLINE; FERROCENE DERIVATIVE; FERROCENYL CHALCONE DERIVATIVE; FERROCENYL PYRROLO[1,2 A]QUINOXALINE DERIVATIVE; FERROCENYL STRYCHNOBRASILINE; FERROQUINE; HEMOZOIN; HYDROXYCHLOROQUINE; MEFLOQUINE; PRIMAQUINE; PROGUANIL; PYRIMETHAMINE; PYRROLOQUINOXALINE DERIVATIVE; QUININE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULFADOXINE; THIOSEMICARBAZONE; TRIAZACYCLONONANE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIMALARIAL ACTIVITY; CLINICAL PRACTICE; CONJUGATE; DRUG BINDING; DRUG EFFICACY; DRUG HALF LIFE; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; LIPOPHILICITY; MALARIA; MALARIA FALCIPARUM; NONHUMAN; OXIDATIVE STRESS; PHASE 2 CLINICAL TRIAL (TOPIC); PLASMODIUM FALCIPARUM; PLASMODIUM KNOWLESI; PLASMODIUM MALARIAE; PLASMODIUM OVALE; PLASMODIUM VIVAX; PRIORITY JOURNAL; REVIEW; TOXOPLASMA GONDII;

ANIMALS; ANTIMALARIALS; DRUG DISCOVERY; FERROUS COMPOUNDS; HUMANS; MALARIA; MODELS, MOLECULAR; PLASMODIUM;

EID: 84860228530     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.12.26     Document Type: Review

References (68)

1. Winstanley P. Chemotherapy for falciparum malaria: The armoury, the problems and the prospects. Parasitol. Today 16(4), 146-153 (2000).
2. WHO. Guidelines for the Treatment of Malaria (2nd Edition). WHO, Geneva, Switzerland (2010).
3. Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM. Evidence of artemisinin-resistant malaria in western Cambodia. New Eng. J. Med. 359(24), 2619-2620 (2008).
4. Agnandji ST, Lell B, Soulanoudjingar SS et al. First results of Phase III trial of RTS,S/AS01 malaria vaccine in African children. New Eng. J. Med. 365(20), 1863-1875 (2011).
5. White NJ. A vaccine for malaria. New Eng. J. Med. 365(20), 1926-1927 (2011).
6. Gasser G, Ott I, Metzler-Nolte N. Organometallic anticancer compounds. J. Med. Chem. 54(1), 3-25 (2011).
7. Jaouen G, Metzler-Nolte N. Medicinal organometallic chemistry. In: Topics in Organometallic Chemistry (Volume 32). Springer Publishing, Berlin, Germany (2010).
8. Gasser G, Metzler-Nolte N. Metal compounds as enzyme inhibitors. In: Bioinorganic Medicinal Chemistry. Alessio E (Ed.). Weinheim, Germany, 351-382 (2011).
9. Dyson PJ, Sava G. Metal-based antitumour drugs in the post genomic era. Dalton Trans. 40(36), 1929-1933 (2006).
10. Blanck S, Maksimoska J, Baumeister J, Harms K, Marmorstein R, Meggers E. About the art of filling protein pockets efficiently with octahedral metal complexes. Angew. Chem. Int. Ed. Engl. doi:10.1002/anie.201108865 (2012) (Epub ahead of print).
11. Biot C, Castro W, BottÉ CY, Navarro M. The therapeutic potential of metal-based antimalarial agents: Implications for the mechanism of action. Dalton Trans. doi:10.1039/C2DT12247B (2012) (Epub ahead of print).
12. Wu X, Wilairat P, Go ML. Antimalarial activity of ferrocenyl chalcones. Bioorg. Med. Chem. Lett. 12(17), 2299-2302 (2002).
13. Domarle O, Blampain G, Agnaniet H et al. In vitro antimalarial activity of a new organometallic analog, ferrocene-chloroquine. Antimicrob. Agents Chemother. 42(3), 540-544 (1998).
14. Itoh T, Shirakami S, Ishida N et al. Synthesis of novel ferrocenyl sugars and their antimalarial activities. Bioorg. Med. Chem. Lett. 10(15), 1657-1659 (2000).
15. Fayolle M, Ionita M, Krishna S, Morin C, Patel AP. Probing structure/affinity relationships for the Plasmodium falciparum hexose transporter with glucose derivatives. Bioorg. Med. Chem. Lett. 16(5), 1267-1271 (2006).
16. Ferreira CL, Ewart CB, Barta CA et al. Synthesis, structure, and biological activity of ferrocenyl carbohydrate conjugates. Inorg. Chem. 45(20), 8414-8422 (2006).
17. Li R, Chen X, Gong B et al. In vitro antimalarial activity of chalcones and their derivatives. J. Med. Chem. 38(26), 5031-5037 (1995).
18. Chen M, Theander TG, Christensen S, Hviid L, Zhai L, Kharazmi A. Licochalcone A, a new antimalarial agent, inhibits in vitro growth of the human malaria parasite Plasmodium falciparum and protects mice from P. yoelii infection. Antimicrob. Agents Chemother. 38(7), 1470 (1994).
19. Wu X, Tiekink ERT, Kostetski I et al. Antiplasmodial activity of ferrocenyl chalcones: Investigations into the role of ferrocene. Eur. J. Pharm. Sci. 27(2-3), 175-187 (2006).
20. Guillon J, Forfar I, Mamani-Matsuda M et al. Synthesis, analytical behaviour and biological evaluation of new 4-substituted pyrrolo [1, 2-A] quinoxalines as antileishmanial agents. Bioorg. Med. Chem. 15(1), 194-210 (2007).
21. Guillon J, Moreau S, Mouray E et al. New ferrocenic pyrrolo[1, 2-A]quinoxaline derivatives: Synthesis, and in vitro antimalarial activity. Bioorg. Med. Chem. 16(20), 9133-9144 (2008).
22. Guillon J, Mouray E, Moreau S et al. New ferrocenic pyrrolo [1, 2-A] quinoxaline derivatives: Synthesis, and in vitro antimalarial activity - part II. Eur. J. Med. Chem. 46(6), 2310-2326 (2011).
23. Razafimahefa D, Pelinski L, Martin MT, Ramanitrahasimbola D, Rasoanaivo P, Brocard J. Synthesis and chloroquine-enhancing activity of Na-deacetyl-ferrocenoyl-strychnobrasiline. Bioorg. Med. Chem. Lett. 15(4), 1239-1241 (2005).
24. Paitayatat S, Tarnchompoo B, Thebtaranonth Y, Yuthavong Y. Correlation of antimalarial activity of artemisinin derivatives with binding affinity with ferroprotoporphyrin IX. J. Med. Chem. 40(5), 633-638 (1997).
25. Delhaes L, Biot C, Berry L et al. Novel ferrocenic artemisinin derivatives: Synthesis, in vitro antimalarial activity and affinity of binding with ferroprotoporphyrin IX. Bioorg. Med. Chem. 8(12), 2739-2745 (2000).
26. Biot C, Delhaes L, Maciejewski LA et al. Synthetic ferrocenic mefloquine and quinine analogues as potential antimalarial agents. Eur. J. Med. Chem. 35(7-8), 707-714 (2000).
27. Baramee A, Coppin A, Mortuaire M, Pelinski L, Tomavo S, Brocard J. Synthesis and in vitro activities of ferrocenic aminohydroxynaphthoquinones against Toxoplasma gondii and Plasmodium falciparum. Bioorg. Med. Chem. 14(5), 1294-1302 (2006).
28. Fichera ME, Roos DS. A plastid organelle as a drug target in apicomplexan parasites. Nature. 390(6658), 407-409 (1997).
29. Dahl EL, Rosenthal PJ. Multiple antibiotics exert delayed effects against the Plasmodium falciparum apicoplast. Antimicrob. Agents Chemother. 51(10), 3485 (2007).
30. Anquetin G, Greiner J, Vierling P. Quinolone-based drugs against Toxoplasma gondii and Plasmodium spp. Curr. Drug Targets Infect. Disord. 5(3), 227-245 (2005).
31. Saleh A, Friesen J, Baumeister S, Gross U, Bohne W. Growth inhibition of Toxoplasma gondii and Plasmodium falciparum by nanomolar concentrations of 1-hydroxy-2-dodecyl-4 (1H) quinolone, a high-Affinity inhibitor of alternative (type II) NADH dehydrogenases. Antimicrob. Agents Chemother. 51(4), 1217 (2007).
32. Winter RW, Kelly JX, Smilkstein MJ, Dodean R, Hinrichs D, Riscoe MK. Antimalarial quinolones: Synthesis, potency, and mechanistic studies. Exp. Parasitol. 118(4), 487-497 (2008).
33. Dubar F, Anquetin G, Pradines B, Dive D, Khalife J, Biot C. Enhancement of the antimalarial activity of ciprofloxacin using a double prodrug/bioorganometallic approach. J. Med. Chem. 52(24), 7954-7957 (2009).
34. Goodman CD, Su V, McFadden GI. The effects of anti-bacterials on the malaria parasite Plasmodium falciparum. Mol. Biochem. Parasitol. 152(2), 181-191 (2007).
35. Dubar F, Wintjens R, Martins-Duarte ÉS et al. Ester prodrugs of ciprofloxacin as DNA-gyrase inhibitors: Synthesis, antiparasitic evaluation and docking studies. Med. Chem. Commun. 2, 430-435 (2011).
36. Biot C, Dessolin J, Ricard I, Dive D. Easily synthesized antimalarial ferrocene triazacyclononane quinoline conjugates. J. Organomet. Chem. 689(25), 4678-4682 (2004).
37. Biot C. PhD thesis. MolÉcules ferrocÉniques antipaludiques. Synthèse, caractÉrisation et activitÉ. University of Lille 1, Lille, France.
38. De D, Krogstad FM, Byers LD, Krogstad DJ. Structure-Activity relationships for antiplasmodial activity among 7-substituted 4-Aminoquinolines. J. Med. Chem. 41(25), 4918-4926 (1998).
39. De D, Krogstad FM, Cogswell FB, Krogstad DJ. Aminoquinolines that circumvent resistance in Plasmodium falciparum in vitro. Am. J. Trop. Med. Hyg. 55(6), 579 (1996).
40. Chibale K, Moss JR, Blackie M, van Schalkwyk D, Smith PJ. New amine and urea analogs of ferrochloroquine: Synthesis, antimalarial activity in vitro and electrochemical studies. Tetrahedron Lett. 41(32), 6231-6235 (2000).
41. Biot C, Daher W, Chavain N et al. Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities. J. Med. Chem. 49(9), 2845-2849 (2006).
42. Biot C, Daher W, Ndiaye CM et al. Probing the role of the covalent linkage of ferrocene into a chloroquine template. J. Med. Chem. 49(15), 4707-4714 (2006).
43. N'Da D, Jaco CB, Peter JS, Lategan C. Synthesis, cytotoxicity and antimalarial activity of ferrocenyl amides of 4-Aminoquinolines. Arzneimittelforschung 60(10), 627-635 (2010).
44. Biot C, Nosten F, Fraisse L, Ter-Minassian D, Khalife J, Dive D. The antimalarial ferroquine: from bench to clinic. Parasite 18(3), 207 (2011).
45. Biot C, Glorian G, Maciejewski LA et al. Synthesis and antimalarial activity in vitro and in vivo of a new ferrocene-chloroquine analogue. J. Med. Chem. 40(23), 3715-3718 (1997).
46. Beagley P, Blackie MAL, Chibale K et al. Synthesis and antiplasmodial activity in vitro of new ferrocene-chloroquine analogues. Dalton Trans. (15), 3046-3051 (2003).
47. Marfurt J, Chalfein F, Prayoga P et al. Ex vivo drug susceptibility of ferroquine against chloroquine resistant isolates of Plasmodium falciparum and P. vivax. Antimicrob. Agents Chemother. 55(9), 4461-4464 (2011).
48. Leimanis M, Jaidee A, Sriprawat K et al. Plasmodium vivax susceptibility to ferroquine. Antimicrob. Agents Chemother. 54(5), 2228-2230 (2010).
49. Mombo-Ngoma G, Supan C, Dal-Bianco M et al. Phase I randomized dose-Ascending placebo-controlled trials of ferroquine-A candidate anti-malarial drug-in adults with asymptomatic Plasmodium falciparum infection. Malar. J. 10(1), 53 (2011).
50. Dubar F, Egan TJ, Pradines B et al. The antimalarial ferroquine: Role of the metal and intramolecular hydrogen bond in activity and resistance. ACS Chem. Biol. 6(3), 275-287 (2010).
51. Dubar F, Bohic S, Slomianny C et al. In situ nanochemical imaging of label-free drugs: A case study of antimalarials in Plasmodium falciparum-infected erythrocytes. Chem. Comm. 48, 910-912 (2012).
52. Martin RE, Marchetti RV, Cowan AI, Howitt SM, BrÖer S, Kirk K. Chloroquine transport via the malaria parasite's chloroquine resistance transporter. Science. 325(5948), 1680-1682 (2009).
53. Biot C, Taramelli D, Forfar-Bares I et al. Insights into the mechanism of action of ferroquine. Relationship between physicochemical properties and antiplasmodial activity. Mol. Pharm. 2(3), 185-193 (2005).
54. Biot C, Chavain N, Dubar F et al. Structure-Activity relationships of 4-N-substituted ferroquine analogues: Time to re-evaluate the mechanism of action of ferroquine. J. Organomet. Chem. 694(6), 845-854 (2009).
55. Dubar F, Khalife J, Brocard J, Dive D, Biot C. Ferroquine, an ingenious antimalarial drug-Thoughts on the mechanism of action. Molecules 13(11), 2900-2907 (2008).
56. Alex A, Millan DS, Perez M, Wakenhut F, Whitlock GA. Intramolecular hydrogen bonding to improve membrane permeability and absorption in beyond rule of five chemical space. Med. Chem. Commun. 2(7), 669-674 (2011).
57. Chavain N, Vezin H, Dive D et al. Investigation of the redox behavior of ferroquine, a new antimalarial. Mol. Pharm. 5(5), 710-716 (2008).
58. Supan C, Mombo-Ngoma G, Dal-bianco M et al. Pharmacokinetics of ferroquine - A second generation 4 amino-quinoline - in asymptomatic carriers of Plasmodium falciparum infections. Antimicrob. Agents Chemother. (2012) (In press).
59. Warhurst DC, Steele JCP, Adagu IS, Craig JC, Cullander C. Hydroxychloroquine is much less active than chloroquine against chloroquine-resistant Plasmodium falciparum, in agreement with its physicochemical properties. J. Antimicrob. Chemother. 52(2), 188-193 (2003).
60. Projean D, Baune B, Farinotti R et al. In vitro metabolism of chloroquine: Identification of CYP2C8, CYP3A4, and CYP2D6 as the main isoforms catalyzing N-desethylchloroquine formation. Drug. Metab. Dispos. 31(6), 748-754 (2003).
61. Daher W, Pelinski L, Klieber S et al. In vitro metabolism of ferroquine (SSR97193) in animal and human hepatic models and antimalarial activity of major metabolites on Plasmodium falciparum. Drug. Metab. Dispos. 34(4), 667-682 (2006).
62. Chavain N, Davioud-Charvet E, Trivelli X et al. Antimalarial activities of ferroquine conjugates with either glutathione reductase inhibitors or glutathione depletors via a hydrolyzable amide linker. Bioorg. Med. Chem. Lett. 17(23), 8048-8059 (2009).
63. Müller T, Johann L, Jannack B et al. A glutathione reductase-catalyzed cascade of redox reactions to bioactivate potent antimalarial 1, 4-naphthoquinones - A new strategy to combat malarial parasites. J. Am. Chem. Soc. 133(30),11557-11571 (2011).
64. Ames JR, Ryan MD, Klyman DL, Kovacic P. Charge transfer and oxy radicals in antimalarial action. Quinones, dapsone metabolites, metal complexes, imunium ions, and peroxides. Free Radic. Biol. Med. 1(5-6), 353-361 (1985).
65. Biot C, Pradines B, Sergeant MH, Gut J, Rosenthal PJ, Chibale K. Design, synthesis, and antimalarial activity of structural chimeras of thiosemicarbazone and ferroquine analogues. Bioorg. Med. Chem. Lett. 17(23), 6434-6438 (2007).
66. Dechy-Cabaret O, Benoit-Vical F, Robert A, Meunier B. Preparation and antimalarial activities of "trioxaquines", new modular molecules with a trioxane skeleton linked to a 4-Aminoquinoline. ChemBioChem 1(4), 281-283 (2000).
67. CoslÉdan F, Fraisse L, Pellet A et al. Selection of a trioxaquine as an antimalarial drug candidate. Proc. Natl Acad. Sci. USA 105(45), 17579-17584 (2008).
68. Bellot F, Cosleedan F, Vendier L, Brocard J, Meunier B, Robert A. Trioxaferroquines as new hybrid antimalarial drugs. J. Med. Chem. 53(10), 4103-4109 (2010).